Efficacy and Safety Profile of Novel Oral Anticoagulants in the Treatment of Left Atrial Thrombosis: A Systematic Review and Meta-Analysis

Overview

Journal Curr Ther Res Clin Exp

Specialty Pharmacology

Date 2022 May 6

PMID 35515958

Authors

Shu-Jie Dong

Cong-Yan Luo

Cui-Lan Xiao

Feng-Zhe Zhang

Lei Li

Zhong-Ling Han

Suo-Di Zhai

Affiliations

Soon will be listed here.

Abstract

Background: The presence of left atrial/left atrial appendage thrombosis is associated with a higher risk of thromboembolic events in patients with atrial fibrillation. The optimal antithrombotic strategy is not established to date.

Objective: Our aim was to compare the efficacy and safety profile of novel oral anticoagulants with warfarin in the treatment of left atrial/left atrial appendage thrombosis.

Methods: We conducted a systematic search in PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and 3 Chinese databases for all randomized controlled trials and cohort studies (PROSPERO, CRD42021238952) from inception to 7 May 2021. Two authors independently performed the articles selection, data extraction, and quality assessment. The efficacy outcome was the resolution of left atrial/left atrial appendage thrombosis, and the safety outcomes were bleeding and stroke/transient ischemic attack.

Results: One randomized controlled trial and 5 cohort studies were included, with a total of 353 patients. Compared with warfarin, novel oral anticoagulants were associated with increased probability of left atrial/left atrial appendage thrombosis resolution (OR = 2.20; 95% CI, 1.35-3.60;  = 0%). Compared with warfarin, novel oral anticoagulants had a similar risk of bleeding (OR = 0.91; 95% CI, 0.39-2.13;  = 0%). There was no evidence of increased risk of stroke/transient ischemic attack (OR = 0.42; 95% CI, 0.12-1.45;  = 0%).

Conclusions: Novel oral anticoagulants were more effective than warfarin in promoting the resolution of left atrial/left atrial appendage thrombosis, without increased risks of bleeding and stroke/transient ischemic attack. Our study provides valuable insight into clinical practice. Further well-designed randomized controlled trials are needed to fully evaluate the benefits and risks in these patients. PROSPERO Registration No.: CRD42021238952.

Citing Articles

Treatment of Persistent Left Atrial Appendage Thrombus in Patients with Atrial Fibrillation on Adequate Oral Anticoagulation: Pathways of Care for All-comers and Heart Failure Patients.

Katic J, Borovac J Card Fail Rev. 2023; 9:e05.

PMID: 37397240 PMC: 10311400. DOI: 10.15420/cfr.2022.28.

References

Da Costa A, Delolme C, Guichard J, Gerbay A, Pierrard R, Romeyer-Bouchard C . Comparison of prevalence and management of left atrial appendage thrombi under old and new anticoagulants prior to left atrial catheter ablation. Am Heart J. 2017; 193:8-15. DOI: 10.1016/j.ahj.2017.07.016. View

Marsico F, Cecere M, Parente A, Paolillo S, De Martino F, Dellegrottaglie S . Effects of novel oral anticoagulants on left atrial and left atrial appendage thrombi: an appraisal. J Thromb Thrombolysis. 2016; 43(2):139-148. DOI: 10.1007/s11239-016-1421-9. View

Miyazawa K, Pastori D, Hammerstingl C, Cappato R, Meng I, Kramer F . Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA). Ann Med. 2018; 50(6):511-518. DOI: 10.1080/07853890.2018.1495337. View

Lip G, Hammerstingl C, Marin F, Cappato R, Meng I, Kirsch B . Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016; 178:126-34. DOI: 10.1016/j.ahj.2016.05.007. View

Mearns E, Kohn C, Song J, Hawthorne J, Meng J, White C . Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients. Thromb Res. 2014; 134(2):310-9. DOI: 10.1016/j.thromres.2014.05.035. View

Wu M, Gabriels J, Khan M, Shaban N, DAmato S, Liu C . Left atrial thrombus despite continuous direct oral anticoagulant or warfarin therapy in patients with atrial fibrillation: insights into rates and timing of thrombus resolution. J Interv Card Electrophysiol. 2018; 53(2):159-167. DOI: 10.1007/s10840-018-0432-1. View

Wallace T, Atwater B, Daubert J, Voora D, Crowley A, Bahnson T . Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2010; 21(8):849-52. DOI: 10.1111/j.1540-8167.2010.01729.x. View

Hussain A, Wang N . Meta-analyses for oral anticoagulants and left atrial appendage thrombus resolution in nonvalvular atrial fibrillation: Piecing the puzzle together. J Cardiovasc Electrophysiol. 2020; 31(8):2261-2262. DOI: 10.1111/jce.14568. View

Blackshear J, ODell J . Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996; 61(2):755-9. DOI: 10.1016/0003-4975(95)00887-X. View

10.

Orenes-Pinero E, Esteve-Pastor M, Valdes M, Lip G, Marin F . Efficacy of non-vitamin-K antagonist oral anticoagulants for intracardiac thrombi resolution in nonvalvular atrial fibrillation. Drug Discov Today. 2017; 22(10):1565-1571. DOI: 10.1016/j.drudis.2017.05.010. View

11.

Bernhardt P, Schmidt H, Hammerstingl C, Hackenbroch M, Sommer T, Luderitz B . Fate of left atrial thrombi in patients with atrial fibrillation determined by transesophageal echocardiography and cerebral magnetic resonance imaging. Am J Cardiol. 2004; 94(6):801-4. DOI: 10.1016/j.amjcard.2004.06.010. View

12.

Hao L, Zhong J, Zhang W, Rong B, Xie F, Wang J . Uninterrupted dabigatran versus warfarin in the treatment of intracardiac thrombus in patients with non-valvular atrial fibrillation. Int J Cardiol. 2015; 190:63-6. DOI: 10.1016/j.ijcard.2015.04.104. View

13.

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

14.

Patel M, Mahaffey K, Garg J, Pan G, Singer D, Hacke W . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-91. DOI: 10.1056/NEJMoa1009638. View

15.

Ke H, He Y, Lv X, Zhang E, Wei Z, Li J . Efficacy and safety of rivaroxaban on the resolution of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation patients. J Thromb Thrombolysis. 2019; 48(2):270-276. DOI: 10.1007/s11239-019-01876-z. View

16.

Scherr D, Dalal D, Chilukuri K, Dong J, Spragg D, Henrikson C . Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2008; 20(4):379-84. DOI: 10.1111/j.1540-8167.2008.01336.x. View

17.

Xing X, Liu N, Han Y, Zhou W, Liang M, Wang Z . Anticoagulation efficacy of dabigatran etexilate for left atrial appendage thrombus in patients with atrial fibrillation by transthoracic and transesophageal echocardiography. Medicine (Baltimore). 2018; 97(26):e11117. PMC: 6039616. DOI: 10.1097/MD.0000000000011117. View

18.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

19.

Park Y, Moon J, Chung W, Shin M, Choi I . Apixaban successfully resolved a warfarin-resistant left atrial appendage thrombus in a patient with end-stage renal disease on hemodialysis. Anatol J Cardiol. 2019; 21(3):174-175. PMC: 6457404. DOI: 10.14744/AnatolJCardiol.2019.66789. View

20.

Piotrowski R, Zaborska B, Pilichowska-Paszkiet E, Sikora-Frac M, Baran J, Kulakowski P . RIVAroxaban TWICE daily for lysis of thrombus in the left atrial appendage in patients with non-valvular atrial fibrillation: the RIVA-TWICE study. Arch Med Sci. 2020; 16(2):289-296. PMC: 7069443. DOI: 10.5114/aoms.2019.86616. View